{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:14:49Z","timestamp":1793672089270,"version":"4.5.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004169","name":"Meiji Seika Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004169","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010391","name":"Tokyo Women's Medical University","doi-asserted-by":"publisher","award":["5082"],"award-info":[{"award-number":["5082"]}],"id":[{"id":"10.13039\/501100010391","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jgar.2021.07.018","type":"journal-article","created":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T05:04:40Z","timestamp":1628399080000},"page":"12-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Candidates for area under the concentration\u2013time curve (AUC)-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients"],"prefix":"10.1016","volume":"27","author":[{"given":"Naoto","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Hanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Chuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akari","family":"Shigemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Takesue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.07.018_bib0001","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/00003088-198611040-00001","article-title":"Clinical pharmacokinetics of vancomycin","volume":"11","author":"Matzke","year":"1986","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jgar.2021.07.018_bib0002","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","article-title":"High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity","volume":"166","author":"Hidayat","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jgar.2021.07.018_bib0003","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.clinthera.2007.06.014","article-title":"A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia","volume":"29","author":"Jeffres","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.jgar.2021.07.018_bib0004","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/jac\/dkn080","article-title":"Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy","volume":"62","author":"Ingram","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.07.018_bib0005","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jac\/dkl030","article-title":"Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia","volume":"57","author":"Sakoulas","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.07.018_bib0006","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1086\/381202","article-title":"Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility","volume":"38","author":"Howden","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"Suppl 5","key":"10.1016\/j.jgar.2021.07.018_bib0007","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.1086\/533592","article-title":"Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains","volume":"46","author":"Sakoulas","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.07.018_bib0008","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jgar.2021.07.018_bib0009","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/jac\/dkz520","article-title":"Attributable nephrotoxicity of vancomycin in critically ill patients: a marginal structural model study","volume":"75","author":"Arnaud","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.07.018_bib0010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01653-13","article-title":"Are vancomycin trough concentrations adequate for optimal dosing?","volume":"58","author":"Neely","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.07.018_bib0011","doi-asserted-by":"crossref","first-page":"e01293","DOI":"10.1128\/AAC.01293-17","article-title":"A quasi-experiment to study the impact of vancomycin area under the concentration\u2013time curve-guided dosing on vancomycin-associated nephrotoxicity","volume":"61","author":"Finch","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.07.018_bib0012","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/phar.2234","article-title":"Conversion from vancomycin trough concentration-guided dosing to area under the curve-guided dosing using two sample measurements in adults: implementation at an academic medical center","volume":"39","author":"Meng","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2021.07.018_bib0013","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/FTD.0000000000000622","article-title":"Examining the relationship between vancomycin area under the concentration time curve and serum trough levels in adults with presumed or documented staphylococcal infections","volume":"41","author":"Clark","year":"2019","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jgar.2021.07.018_bib0014","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/phar.2376","volume":"40","author":"Rybak","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2021.07.018_bib0015","first-page":"1","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.jgar.2021.07.018_bib0016","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jgar.2021.07.018_bib0017","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/cpt.726","article-title":"The nephrotoxicity of vancomycin","volume":"102","author":"Filippone","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jgar.2021.07.018_bib0018","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.07.018_bib0019","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration\u2013time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.07.018_bib0020","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/cpt.726","article-title":"The nephrotoxicity of vancomycin","volume":"102","author":"Filippone","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jgar.2021.07.018_bib0021","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/1060028014556813","article-title":"A randomized trial of loading vancomycin in the emergency department","volume":"49","author":"Rosini","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jgar.2021.07.018_bib0022","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1128\/AAC.01602-07","article-title":"Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.07.018_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222095","article-title":"Vancomycin-associated nephrotoxicity in non-critically ill patients admitted in a Brazilian public hospital: a prospective cohort study","volume":"14","author":"de Almeida","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2021.07.018_bib0024","first-page":"e01684","article-title":"Identification of vancomycin exposure\u2013toxicity thresholds in hospitalized patients receiving intravenous vancomycin","volume":"62","author":"Zasowski","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"10.1016\/j.jgar.2021.07.018_bib0025","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1093\/cid\/ciy680","article-title":"A prospective multicenter clinical observational study on vancomycin efficiency and safety with therapeutic drug monitoring","volume":"67","author":"Liang","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.07.018_bib0026","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/phar.1488","article-title":"Vancomycin-associated renal dysfunction: where are we now?","volume":"34","author":"Carreno","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2021.07.018_bib0027","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/cid\/ciw811","article-title":"Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin\/tazobactam","volume":"64","author":"Hammond","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.07.018_bib0028","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1179\/135100002125000884","article-title":"Inhibition of vancomycin-induced nephrotoxicity by targeting superoxide dismutase to renal proximal tubule cells in the rat","volume":"7","author":"Nishino","year":"2002","journal-title":"Redox Rep"},{"key":"10.1016\/j.jgar.2021.07.018_bib0029","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/00003246-200206000-00013","article-title":"Aminoglycoside and glycopeptide renal toxicity in intensive care patients studied by proton magnetic resonance spectroscopy of urine","volume":"30","author":"Le Moyec","year":"2002","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jgar.2021.07.018_bib0030","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/j.1875-9114.1997.tb03690.x","article-title":"Suspected acute interstitial nephritis induced by piperacillin\u2013tazobactam","volume":"17","author":"Pill","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2021.07.018_bib0031","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/cid\/ciw709","article-title":"Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin\u2013tazobactam compared to those on vancomycin and cefepime","volume":"64","author":"Navalkele","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.07.018_bib0032","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00228-012-1259-9","article-title":"Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review","volume":"68","author":"Elyasi","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jgar.2021.07.018_bib0033","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jiph.2019.09.001","article-title":"Intermittent vs. continuous vancomycin infusion for Gram-positive infections: a systematic review and meta-analysis","volume":"13","author":"Chu","year":"2020","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.jgar.2021.07.018_bib0034","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/CCM.0000000000004326","article-title":"Continuous versus intermittent infusion of vancomycin and the risk of acute kidney injury in critically ill adults: a systematic review and meta-analysis","volume":"48","author":"Flannery","year":"2020","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jgar.2021.07.018_bib0035","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1128\/AAC.45.9.2460-2467.2001","article-title":"Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study","volume":"45","author":"Wysocki","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.07.018_bib0036","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/ALN.0b013e3181a97272","article-title":"Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion","volume":"111","author":"Hutschala","year":"2009","journal-title":"Anesthesiology"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521001880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521001880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:59:41Z","timestamp":1761991181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521001880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":36,"alternative-id":["S2213716521001880"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.07.018","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Candidates for area under the concentration\u2013time curve (AUC)-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}